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A B S T R A C T
Viral interferon (IFN) antagonists are a diverse class of viral proteins that counteract the host IFN response,
which is important for controlling viral infections. Viral IFN antagonists are often multifunctional proteins that
perform vital roles in virus replication beyond IFN antagonism. The critical importance of viral IFN antagonists is
highlighted by the fact that almost all viruses encode one of these proteins. Inhibition of viral IFN antagonists has
the potential to exert pleiotropic antiviral eﬀects and thus this important protein class represents a diverse
plethora of novel therapeutic targets. To exploit this, we have successfully developed and executed a novel
modular cell-based platform that facilitates the safe and rapid screening for inhibitors of a viral IFN antagonist of
choice. The platform is based on two reporter cell-lines that provide a simple method to detect activation of IFN
induction or signaling via an eGFP gene placed under the control of the IFNβ or an ISRE-containing promoter,
respectively. Expression of a target IFN antagonist in the appropriate reporter cell-line will block the IFN re-
sponse and hence eGFP expression. We hypothesized that addition of a compound that inhibits IFN antagonist
function will release the block imposed on the IFN response and hence restore eGFP expression, providing a
measurable parameter for high throughput screening (HTS). We demonstrate assay proof-of-concept by (i) ex-
ploiting hepatitis C virus (HCV) protease inhibitors to inhibit NS3-4A's capacity to block IFN induction and (ii)
successfully executing two HTS targeting viral IFN antagonists that block IFN signaling; NS2 and IE1 from
human respiratory syncytial virus (RSV) and cytomegalovirus (CMV) respectively, two clinically important
viruses for which vaccine development has thus far been unsuccessful and new antivirals are required. Both
screens performed robustly and Z′ Factor scores of> 0.6 were achieved. We identiﬁed (i) four hit compounds
that speciﬁcally inhibit RSV NS2's ability to block IFN signaling by mediating STAT2 degradation and exhibit
modest antiviral activity and (ii) two hit compounds that interfere with IE1 transcription and signiﬁcantly impair
CMV replication. Overall, we demonstrate assay proof-of-concept as we target viral IFN antagonists from un-
related viruses and demonstrate its suitability for HTS.
1. Introduction
Viral interferon (IFN) antagonists are a vital protein class not spe-
ciﬁcally targeted by clinically approved antivirals (De Clercq and Li,
2016). These diverse viral proteins counteract the host IFN system, a
powerful innate immune response important for controlling viral
infections. Upon virus infection, IFN expression is triggered. Secreted
IFN stimulates signaling to activate expression of IFN-stimulated genes
(ISGs), which elicit an antiviral state (Hoﬀmann et al., 2015; Randall
and Goodbourn, 2008).
Viruses have evolved a wide variety of strategies to circumvent the
IFN response (Beachboard and Horner, 2016). The critical importance
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of viral IFN antagonists is highlighted by the fact that almost all viruses
encode at least one antagonist (Versteeg and Garcia-Sastre, 2010).
Genetic studies have demonstrated the importance of viral IFN an-
tagonists in virus replication, virulence and pathogenesis (Fleming,
2016). Disabling viral IFN antagonist function impedes a virus' ability
to counteract the IFN response, predisposing infection in favor of the
host and consequently virus clearance. In addition, viral IFN antago-
nists are often multifunctional proteins that perform vital roles in virus
replication beyond IFN antagonism (Fehling et al., 2012; Hale et al.,
2008). Therefore, inhibition of viral IFN antagonists has the potential to
exert pleiotropic antiviral eﬀects.
To exploit the abundant array of viral IFN antagonists as potential
drug targets our objective was development of a novel modular cell-
based platform that facilitates safe and rapid screening for inhibitors
against any viral IFN antagonist of choice. Towards this aim we pre-
viously generated two reporter cell-lines, A549/pr(IFNβ).GFP and
A549/pr(ISRE).GFP, that provide a simple method to detect activation
of IFN induction or signaling via an eGFP gene under the control of the
IFNβ or an ISRE-containing promoter, respectively (Chen et al., 2010;
Stewart et al., 2014) and demonstrated their suitability for high-
throughput screening (HTS) (Gage et al., 2016). Here we utilize these
validated reporter cell-lines as a platform to target viral IFN antago-
nists. We have shown that viral IFN antagonist expression in the A549/
pr(IFNβ).GFP reporter cell-line blocks the IFN response and hence eGFP
expression (Chen et al., 2010). We hypothesized that addition of a
compound that inhibits IFN antagonist function will release the im-
posed block and hence restore eGFP expression, providing a measurable
parameter for HTS.
For initial proof-of-concept we exploit hepatitis C virus (HCV)
protease inhibitors (PIs); antivirals that inhibit NS3-4A (De Clercq and
Li, 2016), an HCV protein with IFN antagonist function (Xu and Zhong,
2016). PI inhibition of NS3-4A prevents cleavage of the HCV poly-
protein and critical MAVS/TRIF components of the IFN induction
pathway (Kalkeri et al., 2013). For HTS we target IFN antagonists from
two clinically important human viruses, respiratory syncytial virus
(RSV) and cytomegalovirus (CMV), for which vaccine development has
thus far been unsuccessful and new antivirals are required (Griﬃths
et al., 2015, 2017). We target the RSV IFN antagonist non-structural
protein 2 (NS2), which blocks IFN signaling via proteasomal degrada-
tion of signal transducer and activator of transcription 2 (STAT2)
(Barik, 2013; Lo et al., 2005; Ramaswamy et al., 2006). NS2 also plays
an important role in RSV pathogenicity independent of IFN antagonism
(Liesman et al., 2014; Yang et al., 2015). We further target the CMV IFN
antagonist immediate-early 1 protein (IE1), which counteracts IFN
signaling by binding directly to STAT2 thereby preventing the tran-
scription factor complex ISGF3 from binding ISRE elements in the
promoters of ISGs (Paulus et al., 2006). IE1 also plays a crucial role in
the initiation of lytic CMV infection as IE1, along with IE2, stimulate
the transcription of early genes required to replicate viral DNA (Stinski
and Meier, 2007).
2. Materials and methods
2.1. Cell-lines
The A549 cell-line (ECACC) and derivatives (Appendix Table A.1)
were maintained in DMEM with 10% fetal bovine serum (FBS) (DMEM-
10). A549 reporter cell-line derivatives expressing HCV NS3-4A, RSV
NS1/NS2 or PIV5 V were generated using a self-inactivating lentiviral
constitutive expression system (Demaison et al., 2002). A549 reporter
cell-line derivatives expressing CMV IE1 and corresponding negative
controls (luciferase (Luc) and IE1dl410-420 (Harwardt et al., 2016))
were generated using the Lenti-X Tet-One inducible expression system
(Clontech). Lentiviruses were generated in 293T cells (ECACC), used to
transduce the appropriate reporter cell-line and maintained under an-
tibiotic selection. A Hep2 cell-line derivative constitutively expressing
PIV2 V (Precious et al., 2005) or BVDV Npro (Hilton et al., 2006), MRC-
5 cells (ATCC), Vero cells (ECACC) and STAT2-deﬁcient primary skin
ﬁbroblasts (Hambleton et al., 2013) were maintained in DMEM-10.
2.2. Cell-based IFN induction and signaling reporter assays
The A549/pr(IFNβ).GFP and A549/pr(ISRE).GFP reporter assays
have been described (Gage et al., 2016; Stewart et al., 2014). Brieﬂy,
24 h post cell seeding (9 × 104 cells/cm2) the A549/pr(IFNβ).GFP cell-
line is activated by infection with a PIV5VΔC stock rich in defective
interfering (DI) particles (He et al., 2002) or a UV-inactivated pp65-
deﬁcient CMV stock (Buscher et al., 2015) and the A549/pr(ISRE).GFP
cell-line is activated with 104 U/ml puriﬁed IFNα (Roferon, NHS). A549
reporter cell-line derivatives expressing inducible CMV IE1, Luc or
IE1dl410-420 were seeded in the presence or absence of doxycycline
(1 μg/ml). When appropriate, cells were treated with compound 2 h
prior to activation of IFN induction or signaling and assay output was
measured in raw ﬂuorescent units (RFU) using an Inﬁnite-M200-Pro
plate reader (Tecan).
2.3. Compound library, inhibitors and cell viability assays
The compound library used for HTS, termed StA-HTS-Library, was a
kind gift of Professor Westwood, University of St Andrews. The library
(n = 16,000 compounds at 10 mM in DMSO) consists of the Maybridge
HitFinder™ Collection (n = 14,400 compounds, ThermoFisher
Scientiﬁc; selected by Maybridge to represent drug-like diversity of the
Maybridge Screening Collection) supplemented with 1600 compounds
that have been synthesized in-house by Professor Westwood. Hit com-
pounds StA-NS2-1 (ethyl2-(1H-indol-3 ylmethylidene)hydrazine-1-car-
boxylate), StA-NS2-2 (N-(1H-indazol-3-yl)-3-methoxybenzamide), StA-
NS2-3 (1H-indol-3-yl)butan-2-one), StA-NS2-4 (methyl 2-aminothio-
phene-3-carboxylate), StA-IE1-1 (7-(4-ﬂuorophenyl)-6a,7-dihydro-6H-
chromeno[3,4-c][1,5]benzothiazepine), StA-IE1-2 (1-(3-nitrophenyl)-
2-(pyrido[3,2-d][1,3]thiazol-2-ylthio)ethan-1-one), and StA-IE1-3 (1-
(3,5-dichloro-4-pyridinyl)-4-piperidinecarboxamide) where re-
purchased from Maybridge (ThermoFisher Scientiﬁc) and stored as
20 mM stocks in DMSO. Compound purity was determined by the
manufacturer and ranged from 90 to 97%. HCV PI Danoprevir
(Selleckchem), RSV RNA polymerase inhibitor ASL-8112
(MedChemExpress) and CMV DNA polymerase inhibitor ganciclovir
(GCV) (Calbiochem) were stored as 20 mM stock in DMSO. Commercial
cell-viability assays (AlamarBlue, PrestoBlue (ThermoFisher Scientiﬁc)
or CellTiter 96 AQueous One Solution (Promega)) were performed ac-
cording to manufacturer instructions. Crystal violet staining determined
cell density by measuring absorbance at 570 nm (Inﬁnite-M200-Pro
plate reader, Tecan).
2.4. HTS and dose-response assays
Single-point HTS was performed using the A549/pr(ISRE).GFP-RSV-
NS2 and A549/pr(ISRE).GFP-CMV-IE1 cell-lines and the StA-HTS-
Library. The A549/pr(ISRE).GFP reporter assay was used with the fol-
lowing variations. Cells were seeded (9 × 104 cells/cm2) in 384-well
plates and 11 μM of compound was added using a MiniTrak liquid
handler (PerkinElmer) 2 h prior to IFNα activation. HTS screening data
output was analyzed as fold-increase in eGFP expression calculated as:
Fold increase eGFP = μ (RFUTest)/μ (RFUUninduced) (A.1)
HTS quality control criteria for the acceptance of an assay plate
were as follows: signal-to-background (S/B) ratio ≥2-fold, coeﬃcient
of variation (CV) < 8% ((σ/μ)*100) and Z′ Factor ≥0.5 (Eq. (A2))
(Gage et al., 2016). Each appropriate statistical parameter was de-
termined for each assay plate and the overall screen.
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Z′ Factor = 1−[(3 (σUninduced + σInduced))/| μUninduced−μInduced |]
(A.2)
Dose response curves were performed via nine-point two-fold serial
dilution (50–0.1 μM). For determination of potency, a four-parameter
logical ﬁt of the following form was used:
Y = B + [(T−B)/(1 + (EC50)/X)h] (A.3)
B = baseline response (bottom asymptote), T = maximum response
(top asymptote), h = slope (Hill coeﬃcient) and EC50 = compound
concentration 50% between baseline and maximum.
2.5. Protein analyses
Preparation of whole cell protein, SDS-PAGE, immunoblotting, in-
direct immunoﬂuorescence microscopy and co-immunoprecipitation
analyses were performed according to previously published protocols
(Gage et al., 2016; Harwardt et al., 2016; Krauss et al., 2009; Nevels
et al., 2004). Appendix Table A.2 provides details of primary anti-
bodies. HRP-conjugated secondary antibodies were used for visualiza-
tion via enhanced chemiluminesence and IRDye 800CW- or IRDye
680RD-conjugated secondary antibodies were used for visualization
and quantiﬁcation via an Odyssey CLx near-infrared scanner (Li-Cor).
2.6. Virological assays
rRSV-WT, rRSV-GFP (Rameix-Welti et al., 2014) and PIV5mCherry
(kind gift of Dr He, University of Georgia, USA) were propagated in
Hep2-BVDV/Npro cells (Hilton et al., 2006) and stock titer determined.
Virus infections were performed at the indicated MOI and, where ap-
propriate, treated at the indicated time and concentration with StA-
NS2-2, DMSO and/or 104 U/ml IFNα. rRSV-GFP and PIV5mCherry
virus replication was monitored overtime by (i) eGFP or mCherry
expression respectively, using an Inﬁnite-M200-Pro plate reader or (ii)
determining rRSV-GFP infectious titer (PFU/ml) in supernatant har-
vested at 24, 48, 72 and 96 h post infection. Infectious titer was de-
termined via plaque assay using Hep2-BVDV-Npro cells and a 1% me-
thyl cellulose (Sigma-Aldrich) overlay in DMEM supplemented with 2%
FBS. Plaques were visualized after 4 days using a BioRad ChemiDoc MP
imaging system and an XcitaBlue conversion screen. CMV gTBwt, an
eGFP expressing version of the TB40E strain (Harwardt et al., 2016;
Sinzger et al., 2008; Umashankar et al., 2011), was reconstituted and
virus stocks were produced on electroporation of MRC-5 cells with BAC
DNA. Stock titer was determined and IE1 mRNA levels measured by RT-
qPCR with primers 471 and 472 as described in Harwardt et al. (2016)
with the following modiﬁcations. The 2 × concentrated Brilliant III
Ultra-Fast SYBR Green Low ROX QPCR Master Mix and Mx3005P QPCR
System (Agilent Technologies) were used. The relative amount of viral
DNA in culture supernatants was determined using procedures pre-
viously described (Harwardt et al., 2016). For CMV plaque reduction
assays human ﬁbroblasts were pretreated with compound or solvent 2 h
before inoculation with 50 PFU of gTBwt. Infection was performed for
2 h in the presence of solvent or compound. Post-infection cells were
overlaid with 1% methyl cellulose in DMEM supplemented with 2% FBS
and the appropriate concentration of solvent or compound. Cultures
were incubated for 7 days (MRC-5 cells) or 11 days (STAT2-deﬁcient
dermal ﬁbroblasts) before plaques were counted using an EVOS FL Cell
Imaging System with Plan achromat 4 × Objective and GFP Light Cube.
Foci of three or more ﬂuorescent cells were counted as plaques. All
plaque assays were performed in triplicate.
3. Results and discussion
3.1. Assay proof-of-concept using HCV PIs
We hypothesized that our validated A549/pr(IFNβ).GFP and A549/
Fig. 1. Restoration of eGFP expression in activated A549/pr(IFNβ).GFP-NS3-4A reporter cells by the HCV PI Danoprevir. (A) Detection of NS4A and β-actin in A549/pr(IFNβ).GFP
or A549/pr(IFNβ).GFP-NS3-4A reporter cells. Cells were lysed and subjected to SDS-PAGE/Western blot, followed by detection with anti-V5 or anti-actin antibody and HRP-conjugated
secondary antibody. Bands were visualized by chemiluminescence. (B) Eﬀect of NS3-4A on eGFP reporter gene expression upon activation of the IFN induction pathway. A549/pr
(IFNβ).GFP or A549/pr(IFNβ).GFP-NS3-4A reporter cells were infected with PIV5.VΔC to activate the IFN induction pathway. Sixteen hours post-infection eGFP expression was measured
as raw ﬂuorescent units (RFU). Statistical signiﬁcance was assessed using a two-way ANOVA test: ****, p < 0.0001. Data shown represents mean values (n = 6 replicates; error
bars = SD) and is representative of at least 3 independent experiments. (C) Eﬀect of HCV PI Danoprevir on restoration of eGFP expression upon activation of the IFN induction pathway.
A549/pr(IFNβ).GFP or A549/pr(IFNβ).GFP-NS3-4A reporter cells were treated with Danoprevir using a 6-point dose response curve (10-fold dilution series 0.05 nM-5 μM) or equivalent
volume of DMSO (control). Two hours post-compound treatment cells were infected with PIV5VΔC. Sixteen hours post-infection eGFP expression was measured and % eGFP calculated
relative to non-treated/PIV5.VΔC-infected A549/pr(IFN-β)GFP reporters cells, which represent 100%. Data shown represents mean values (n = 3 replicates; error bars = SD) and is
representative of at least 3 independent experiments.
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pr(ISRE).GFP reporter assays (Gage et al., 2016; Stewart et al., 2014)
may be used as a platform to target viral IFN antagonists to discover
novel antiviral compounds. To test this we generated a A549/pr
(IFNβ).GFP cell-line derivative constitutively expressing HCV genotype
1b NS3-4A (A549/pr(IFNβ).GFP-NS3-4A) (Fig. 1A) and exploited HCV
PIs inhibiting NS3-4A's capacity to block IFN induction (Kalkeri et al.,
2013). As expected, PIV5VΔC infection of the A549/pr(IFNβ).GFP cell-
line activated the IFN induction pathway and hence eGFP expression
(Fig. 1B). In contrast, eGFP expression in PIV5VΔC-infected A549/pr
(IFNβ).GFP-NS3-4A cells was almost completely blocked, indicating
that NS3-4A is functional in the reporter cell-line (Fig. 1B). Addition of
HCV PI Danoprevir (Deutsch and Papatheodoridis, 2010) to PIV5VΔC-
infected A549/pr(IFNβ).GFP-NS3-4A cells resulted in a dose-dependent
restoration of eGFP expression (Fig. 1C). These results provide proof-of-
concept that addition of a compound inhibiting IFN antagonist function
can release the block imposed on the IFN response pathway via re-
storation of eGFP expression, providing a measurable parameter for
HTS.
3.2. HTS for inhibitors of RSV NS2
To target RSV NS2 we generated an A549/pr(ISRE).GFP derivative
that constitutively expresses NS2 (Fig. 2A). STAT2 levels are sig-
niﬁcantly reduced in the A549/pr(ISRE).GFP-NS2 cell-line (Fig. 2A),
conﬁrming that NS2 antagonizes IFN signaling via STAT2 proteasomal
degradation. As expected, IFN signaling was activated in IFN-treated
A549/pr(ISRE).GFP cells and resulted in eGFP expression (Fig. 2B). In
contrast, eGFP expression in IFN-treated A549/pr(ISRE).GFP-NS2 cells
was signiﬁcantly reduced, indicating that NS2 is functional in the re-
porter cell-line (Fig. 2B). Levels of the ISG MxA were also signiﬁcantly
reduced in IFN-treated A549/pr(ISRE).GFP-NS2 cells (Fig. 2C), con-
ﬁrming NS2 functionality independent of the eGFP reporter gene. Thus
the A549/pr(ISRE).GFP-NS2 reporter cell-line is suitable for an HTS
campaign to target NS2.
A single-point primary HTS against the A549/pr(ISRE).GFP-NS2
cell-line was performed using the StA-HTS-Library. We ﬁrst conﬁrmed
that the A549/pr(ISRE).GFP reporter assay is suitable for HTS via Z′
Factor, S/B ratio and CV analysis (Fig. 3A and (Gage et al., 2016)).
Following this analysis, the A549/pr(ISRE).GFP-NS2 cell-line was used
to conduct the HTS (Fig. 3B). Due to a lack of an existing positive
control for NS2 inhibition, each well contained IFN-treated A549/pr
(ISRE).GFP-NS2 cells and a single test compound. The lack of a positive
control of NS2 inhibition also meant that statistical validation of the
A549/pr(ISRE).GFP-NS2 cell-line via S/B ratio and Z′ Factor is not
possible as NS2 expression blocks eGFP expression and hence the signal
window required to calculate these parameters. However, CV analysis
remained valid and was within the HTS quality control threshold
(Fig. 3A), indicating that NS2 expression does not alter assay
Fig. 2. Characterization of the A549/pr(ISRE).GFP-NS2 reporter cell-line. (A) Detection of NS2, STAT2 and β-actin in A549/pr(IFNβ).GFP or A549/pr(ISRE).GFP-NS2 reporter cells.
Cells were lysed and subjected to SDS-PAGE/Western blot, followed by detection with anti-myc, anti-STAT2 and anti-β-actin antibody and IRDye680-conjugated secondary antibody.
Bands were visualized using an Odyssey near-infrared scanner and STAT2 levels quantiﬁed as % STAT2 relative to β-actin. Statistical signiﬁcance was assessed using a two-tailed paired T-
test; ***, p < 0.0005. Data shown represents mean values from four independent experiments; error bar = SD. (B) Eﬀect of NS2 on eGFP reporter gene expression upon activation of the
IFN signaling pathway. A549/pr(ISRE).GFP or A549/pr(ISRE).GFP-NS2 reporter cells were incubated with IFNα to activate the IFN signaling pathway. Forty-eight hours post-IFNα
treatment, eGFP expression was visualized and measured as raw ﬂuorescent units (RFU). Data shown represents three independent experiments each with 12 replicates; error bars = SD.
Statistical signiﬁcance was assessed using a two-way ANOVA with Tukey's multiple comparisons test; ****, p < 0.0001. (C) Eﬀect of NS2 on ISG MxA expression upon activation of the
IFN signaling pathway. A549/pr(ISRE).GFP or A549/pr(ISRE).GFP-NS2 reporter cells were incubated with IFNα. Sixteen hours post-IFNα treatment, cell lysates were subjected to SDS-
PAGE/Western blot followed by detection with anti-MxA, anti-myc or anti-actin antibody and IRDye800-conjugated secondary antibody. Bands were visualized using an Odyssey near-
infrared scanner and MxA levels quantiﬁed as % MxA relative to β-actin. Statistical signiﬁcance was assessed using a two-way ANOVA with Tukey's multiple comparisons test; ****,
p < 0.0001, **, p < 0015. Data shown represents mean values from four independent experiments; error bar = SD.
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variability. A normal distribution of fold-increase in eGFP expression
was observed, indicating that the screen performed as expected
(Fig. 3C). A hit was designated as having restored eGFP expression le-
vels ≥1.7-fold above the non-activated A549/pr(ISRE).GFP-NS2 cell-
line level and ≥3 SDs above the test well average for the plate. These
criteria resulted in 28 putative hit compounds and a primary screen hit
rate of 0.18%.
These 28 compounds were cherry-picked from the StA-HTS-Library
and re-tested by dose response screening in (i) the A549/pr(ISRE).GFP-
NS2 reporter assay to conﬁrm eGFP restoration and (ii) cell-free media
to identify auto-ﬂuorescent compounds. Twenty compounds were
eliminated due to auto-ﬂuorescence or lack of activity upon re-testing.
The remaining 8 compounds exhibited dose-dependent eGFP restora-
tion without auto-ﬂuoresence and the best four compounds (Fig. 3D),
named StA-NS2-1, -2, -3 and -4, repurchased. Repurchased compounds
exhibited dose-dependent eGFP restoration in IFN-treated A549/pr(IS-
RE).GFP-NS2 cells (Fig. 3E) with EC50 values in the μM range (Fig. 3F).
To eliminate the possibility that the four hit compounds were false
positives we demonstrated that the repurchased compounds did not: (i)
exhibit auto-ﬂuorescence, (ii) cause non-speciﬁc up-regulation of eGFP,
(iii) disrupt NS2 expression or proteolytic processing, (iv) aﬀect cell
viability (Appendix Fig. B.1). Overall, our data suggest that compounds
StA-NS2-1, -2, -3 and -4 can be considered conﬁrmed hits.
3.3. Hit compounds speciﬁcally inhibit RSV NS2 function and exhibit
antiviral activity
As compounds StA-NS2-1, -2 and -3 are structurally related (Fig. 3D)
only StA-NS2-2 was taken forward for further study. StA-NS2-2 raised
MxA and STAT2 levels in IFN-treated A549/pr(ISRE).GFP-NS2 cells
(Fig. 4A), suggesting that StA-NS2-2 partially restores the IFN signaling
pathway by inhibiting NS2 function.
StA-NS2-2 speciﬁcity against RSV NS2 was investigated using
A549/pr(ISRE).GFP cell-line derivatives expressing unrelated viral IFN
antagonists that block IFN signaling. Derivatives used constitutively
express (i) PIV5 IFN antagonist V (Didcock et al., 1999), (ii) RSV's other
IFN antagonist non-structural protein 1 (NS1), which imposes a mod-
erate IFN signaling block when expressed independently from NS2 but
not via STAT2 degradation (Lo et al., 2005; Ramaswamy et al., 2006;
Swedan et al., 2009) and (iii) a double reporter cell-line that expresses
RSV NS1 and NS2. Dose-dependent eGFP restoration was only observed
when NS2 was present, either independently or in combination with
NS1 (Fig. 4B). The inability of StA-NS2-2 to reverse the block imposed
by PIV5 V, which mediates STAT1 degradation (Didcock et al., 1999),
Fig. 3. Single-point high-throughput screen to identify compounds that inhibit RSV NS2-mediated antagonism of the IFN signaling pathway. (A) Screen statistics for the A549/
pr(ISRE).GFP and A549/pr(ISRE).GFP-NS2 reporter assays compared with preset quality control (QC) standards. S/B, signal-to-background ratio; CV, coeﬃcient of variation. (B) HTS
assay procedure and timing of treatments. (C) A single point HTS screen was performed using the A549/pr(ISRE).GFP-NS2 reporter cell-line and StA-HTS-Library (n = 16,000 com-
pounds). Screen output, represented as fold increase in eGFP expression and plotted as a frequency distribution of all compounds tested. (D) Repurchased hit compound chemical
structures. (E) Hit compound retesting using the A549/pr(ISRE).GFP-NS2 reporter assay and a 10-point dose-response curve (two-fold serial dilution series 50–0.1 μM). Data shown
represents mean values (n = 6 replicates; error bars = SD) and is representative of at least 3 independent experiments. (F) Dose-response curve-generated EC50 (μM), maximum,
minimum and Hill slope values using Prism 6 Software (GraphPad Software).
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suggests that the compound is not a general inhibitor of proteasomal
machinery. To further verify this we show that StA-NS2-2 does not
reverse the IFN signaling block imposed by PIV2 V, which like NS2
mediates the block via STAT2 proteasomal degradation (Andrejeva
et al., 2002) (Fig. 4C). Our data suggest that StA-NS2-2 speciﬁcally
inhibits RSV NS2 activity.
Next, we determined StA-NS2-2 activity in the context of rRSV-WT
virus infection in A549 cells. StA-NS2-2 raised STAT2 and MxA levels in
virus infected cells independent of exogenous IFN activation (Fig. 5),
suggesting that StA-NS2-2 can partially reverse the IFN signaling block
imposed by rRSV-WT by inhibiting NS2 function. Finally, we sought to
determine if StA-NS2-2 was capable of inhibiting RSV replication in
A549 cells. As replication assays are performed over several days, we
ﬁrst conﬁrmed that StA-NS2-2 retained activity for up to six days in
growth media (Appendix Fig. B.2). In the ﬁrst instance, we monitored
virus replication via GFP reporter gene expression from the rRSV-GFP
genome (Fig. 6A) and demonstrated that StA-NS2-2 modestly inhibited
rRSV-GFP replication. In contrast, PIV5mCherry replication was not
aﬀected by StA-NS2-2 (Fig. 6B), consistent with our data demonstrating
the compound does not reverse the IFN signaling block imposed by
PIV5 V (Fig. 4B). StA-NS2-2 did not aﬀect cell viability (Fig. 6C). Fi-
nally, to conﬁrm the antiviral eﬀect of StA-NS2-2 we examined in-
fectious titer produced from compound-treated A549 cells (Fig. 6D) and
IFN-deﬁcient Vero cells (Fig. 6E). The RSV polymerase inhibitor ASL-
8112 (Clarke et al., 2015; Wang et al., 2015) potently inhibited RSV in
both cell types. As expected, StA-NS2-2 exhibited modest antiviral ac-
tivity in A549 cells but had no signiﬁcant eﬀect in Vero cells, suggesting
that StA-NS2-2 is acting solely on the IFN antagonistic function of NS2.
In summary, we have identiﬁed compounds that speciﬁcally inhibit
RSV NS2 IFN antagonist function. As these compounds only partially
restore IFN signaling and exhibit relatively modest antiviral activity, a
medicinal chemistry campaign is now required to optimize potency.
Fig. 4. Speciﬁcity of hit compound StA-NS2-2. (A) Eﬀect of StA-NS2-2 on MxA and STAT2 levels. A549/pr(ISRE).GFP and A549/pr(ISRE).GFP-NS2 cells were treated with StA-NS2-2 or
equivalent volume of DMSO. Two hours post-compound treatment, IFNα was used to activate the IFN signaling pathway. Sixteen hours post-IFNα, cells were lysed, subjected to SDS-
PAGE/Western blot, followed by detection with anti-STAT2, anti-MxA, anti-myc or anti-actin antibody and IRDye800-conjugated secondary antibody. Bands were visualized using an
Odyssey near-infrared scanner, followed by quantiﬁcation of % STAT2 and % MxA relative to β-actin. Data shown represents mean values from 3 independent experiments; error
bars = SD. Statistical signiﬁcance was assessed using two-way ANOVA with Turkey's multiple comparison test to compare eﬀect of StA-NS2-2 on STAT2 or MxA levels in αIFN-treated
A549/(ISRE).GFP-NS2 cells; ***, p < 0.0005, **, p < 0.005. (B) StA-NS2-2 activity is speciﬁc to RSV NS2 and not unrelated viral IFN antagonists RSV NS1 or PIV5 V. A549/pr
(ISRE).GFP derivatives expressing RSV NS2, RSV NS1, RSV NS1+NS2 or PIV5 V were treated with StA-NS2-2 using 10-point dose-response curve (two-fold serial dilution series
50–0.1 μM). Two hours post-compound treatment, IFNα treatment activated the IFN signaling pathway. Forty-eight hours post-IFNα treatment, eGFP expression was measured and fold-
increase calculated. Data shown represents mean values (n = 4 replicates; error bars = SD) and is representative of at least 3 independent experiments. (C) StA-NS2-2 activity is speciﬁc
to RSV NS2 and not PIV2 V protein. Hep2 and Hep2-PIV2/V cell-lines were treated with StA-NS2-2 or equivalent volume of DMSO. Two hours post-compound treatment, IFNα was used
to activate the IFN signaling pathway. Sixteen hours post-IFNα treatment, cells were lysed, subjected to SDS-PAGE/Western blot, followed by detection with anti-STAT2, anti-V5 or anti-
actin antibody and IRDye800-conjugated secondary antibody. Bands were visualized using an Odyssey near-infrared scanner, followed by quantiﬁcation of % STAT2 relative to β-actin.
Data shown represents mean values from 3 independent experiments; error bars = SD.
A. Vasou et al. Antiviral Research 150 (2018) 79–92
84
More potent compounds will enable further exploration of NS2's po-
tential as a therapeutic target and facilitate mechanism of action studies
to determine if active compounds directly bind NS2 or currently un-
known host cell factors involved in NS2-mediated STAT2 degradation.
Indeed, active compounds represent potentially useful chemical tools to
help elucidate the unresolved molecular mechanism by which NS2
mediates STAT2 degradation. Our approach targeting RSV NS2 is novel
and, to the best of our knowledge, this is the ﬁrst report of compounds
that inhibit RSV NS2. The successful HTS campaign targeting NS2 en-
couraged us to expand our study to target the unrelated CMV IFN an-
tagonist IE1.
3.4. A549/pr(ISRE).GFP-derived cell-line expressing inducible CMV IE1
IE1 is arguably the main IFN antagonist of human CMV (Paulus
et al., 2006) and an unexploited drug target. The continued presence of
IE1 is incompatible with genomic integrity and normal cell prolifera-
tion (Castillo et al., 2005; Shen et al., 1997). Therefore, a doxycycline-
dependent inducible IE1 expression system was used to generate an
A549/pr(ISRE).GFP-IE1 derivative. IE1 expression in the presence or
absence of doxycycline was validated via immunoﬂuorescence micro-
scopy (Fig. 7A) and Western blotting (Fig. 7B). In the absence of
doxycycline, IE1 was undetectable. However, (nuclear) IE1 was readily
detected in the presence of the inducer (Fig. 7A and B). Co-im-
munoprecipitation analysis conﬁrmed that IE1 and STAT2 physically
interact in A549/pr(ISRE).GFP-IE1 cells (Fig. 7C). In contrast, no
complex formation was observed in an A549/pr(ISRE).GFP-derived
cell-line where a mutant IE1 (IE1dl410-420) lacking the STAT binding
motif (Harwardt et al., 2016) was expressed at levels comparable to the
WT protein (Fig. 7C). As expected, IFNα treatment triggered the ac-
cumulation of eGFP in uninduced A549/pr(ISRE).GFP cells (Fig. 7D and
E). Expression of WT IE1, but not IE1dl410-420 or Luc, completely
blocked IFNα-induced eGFP accumulation (Fig. 7D) and ﬂuorescence
(Fig. 7E and F). To conﬁrm speciﬁcity for the ISRE containing promoter,
we generated A549/pr(IFNβ).GFP cell-line derivatives expressing in-
ducible WT and mutant IE1. IE1 did not block eGFP accumulation in-
duced by UV-inactivated CMV in these cells (Fig. 7D), conﬁrming that
the viral protein does not aﬀect the type I IFN response upstream of
JAK-STAT signaling (Paulus et al., 2006). These results indicate that the
A549/pr(ISRE).GFP-IE1 cell-line is suitable for an HTS campaign to
target CMV IE1.
Fig. 5. Eﬀect of StA-NS2-2 in the context of rRSV-WT infection. Eﬀect of StA-NS2-2 on MxA and STAT2 levels following infection of A549 cells with rRSV-WT. Infected cells were
treated with StA-NS2-2 or the equivalent volume of DMSO. Six hours post-compound treatment, IFNα was used to activate the IFN signaling pathway. Twelve-hours post-IFNα treatment,
cells were lysed, subjected to SDS-PAGE/Western blot, followed by detection with anti-STAT2, anti-MxA, anti-RSV-M or anti-actin antibody and IRDye680-or IRDye800-conjugated
secondary antibody. Bands were visualized using an Odyssey near-infrared scanner, followed by quantiﬁcation of % STAT2 and MxA levels relative to β-actin. Data shown represents
mean values from 3 independent experiments; error bars = SD. Statistical signiﬁcance was assessed using a one-way ANOVA with Tukey's multiple comparison test to compare eﬀect of
StA-NS2-2 on STAT2 and MxA levels in rRSV-WT infected cells; *, p < 0.05, **, p < 0.005, ****, p < 0.0001.
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3.5. HTS for inhibitors of CMV IE1
A single-point primary HTS against the A549/pr(ISRE).GFP-IE1 cell-
line was performed using the StA-HTS-Library. The 384-well plate
layout with positive and negative controls and the timing of treatments
are shown in Fig. 8A and B, respectively. We conﬁrmed that the A549/
pr(ISRE).GFP-IE1 cell-line is suitable for HTS via S/B ratio (Fig. 8C), CV
(Fig. 8D) and Z′ Factor (Fig. 8E) analysis. Our predetermined QC cri-
teria were achieved, with the exception of S/B ratio, which was low
(μ = 1.45; QC > 2). While a high S/B ratio is preferable, the im-
portance of this parameter is overridden by the excellent Z′ factor score
(μ = 0.71; QC > 0.5), which better indicates assay quality as it takes
into account both the assay signal window (S/B ratio) and data varia-
bility (Zhang et al., 1999). To be considered a hit, a compound had to
restore eGFP ﬂuorescence intensity to ≥3 SDs above the test well
average of the plate. This resulted in 51 hits and a primary screen hit
rate of 0.32%. A total of 33 hits were excluded from further analyses,
because they were identiﬁed in other screens involving A549/pr(IS-
RE).GFP reporter cells. The remaining 18 compounds were cherry-
picked from the StA-HTS-Library. Fifteen compounds were eliminated
due to auto-ﬂuorescence or lack of activity upon re-testing. The
remaining three compounds (StA-IE1-1, StA-IE1-2 and StA-IE1-3) were
repurchased (Fig. 9A).
The StA-IE1 compounds had no eﬀect on eGFP protein levels in the
parental ISRE reporter cell line and in reporter cells constitutively ex-
pressing RSV NS2 (Fig. 9B). Equally, StA-IE1-1, StA-IE1-2 and StA-IE1-3
did not aﬀect eGFP levels in doxycycline-induced Luc control cells, but
the StA-IE1 compounds restored eGFP expression in IFNα-treated
A549/pr(ISRE).GFP-IE1 cells with varying eﬃciencies (Fig. 9C). Sur-
prisingly, StA-IE1-2 and StA-IE1-3, which shared no obvious structural
similarities (Fig. 9A), markedly reduced steady-state IE1 protein levels
without aﬀecting the accumulation of a cellular control protein
(Fig. 9C).
3.6. Eﬀects of hit compounds on CMV gene expression and replication
We investigated whether the hit compounds aﬀect the accumulation
of viral proteins including IE1 during CMV infection. MRC-5 cells were
infected with CMV and subjected to Western blotting (Fig. 10A). Both
StA-IE1-2 and StA-IE1-3 reduced the levels of IE1 and IE2 without af-
fecting the accumulation of the viral tegument protein pp65 or α-tu-
bulin. These results largely exclude oﬀ-target eﬀects on virus entry into
Fig. 6. Eﬀect of StA-NS2-2 on replication of rRSV-GFP and PIV5mCherry. A549 cells were treated with StA-NS2-2 (5 μM) or the equivalent volume of DMSO 24 h prior to infection
with (A) rRSV-GFP or (B) PIV5mCherry at an MOI of 2.5 for 1 h at 37 °C. Mock-infected cells were subjected to the same procedure but incubated with media instead of virus stock.
Following infection cells were maintained in DMEM containing 1% FBS and StA-NS2-2 (5 μM) or the equivalent volume of DMSO. Fluorescence (GFP or mCherry) was monitored as RFU
every 24 h post-infection. (C) In parallel, mock-infected A549 cells were treated as above and % cell viability monitored using PrestoBlue cell viability reagent at each time point. DMSO-
treated cells were set at 100% viability. Data shown represents mean values (n = 4 replicates; error bars = SD) and is representative of at least 3 independent experiments. (D and E)
A549 or Vero cells were treated with StA-NS2-2 (5 μM) or the equivalent volume of DMSO 24 h prior to infection with rRSV-GFP (MOI 1). Following infection cells were maintained in
DMEM containing 1% FBS and StA-NS2-2 (5 μM) or the equivalent volume of DMSO. At 24, 48, 72 and 96 h post infection supernatant was collected and stored at−80 °C. Infectious titer
was determined by plaque assay using HEP2-BVDV-Npro cells. Each plaque assay was performed in triplicate and average titer (PFU/mL) determined. Data is presented as % of DMSO,
which is set at 100% and represents the average of 3 independent experiments (n = 3; error bars = SD). Statistical signiﬁcance was assessed using two-way ANOVA with Dunnett's
multiple comparison test to compare eﬀect of test compounds compared to DMSO control; *, p < 0.05, ***, p < 0.001, ****, p < 0.0001.
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cells. The third hit compound, StA-IE1-1, had little eﬀect on any of the
tested proteins. The reduction of IE1 protein levels by StA-IE1-2 and
StA-IE1-3 is unlikely to be a consequence of eﬀects at the protein level,
but rather results from repressed transcription since the IE1 mRNA le-
vels also decrease in the presence of the two compounds (Fig. 10B).
To investigate whether the hit compounds exhibit antiviral activity,
eGFP expression from the CMV genome was assessed by ﬂuorescence
microscopy. In the presence of StA-IE1-2 and StA-IE1-3, but not StA-
IE1-1, eGFP expression was dramatically reduced compared to control
cells treated with solvent (Fig. 10C). Dose response analyses revealed
that CMV replication was impaired by both StA-IE1-2 and StA-IE1-3
with an EC50 of approximately 0.3 or 1.3 μM, respectively (Fig. 10D).
The reduction in viral replication was not due to cytotoxic eﬀects, since
neither of the two eﬀective compounds induced signiﬁcant cell death
within the tested range of concentrations (Fig. 10E). Consistent with the
ﬂuorescence analysis, viral particle production from cells treated with
StA-IE1-2 or StA-IE1-3 was reduced compared to cells treated with StA-
IE1-1 or solvent (Fig. 10F).
Fig. 7. Characterization of the A549/pr(ISRE).GFP-IE1 reporter cell-line. (A) Immunoﬂuorescence analysis of IE1 expression. A549/pr(ISRE).GFP-IE1 cells were treated with
doxycycline for 24 h (w/Dox) or left untreated (w/o Dox). Paraformaldehyde-ﬁxed samples were examined for IE1 expression using mouse anti-IE1 and Alexa Fluor 594 goat anti-mouse
antibodies. Staining with 4′,6-diamidino-2-phenylindole (DAPI) was performed to visualize nuclei. (B) Western blot analysis of IE1 expression. A549/pr(ISRE).GFP-IE1 cells (A549) were
treated with doxycycline for 24 h (w/Dox) or left untreated (w/o Dox), and MRC-5 ﬁbroblasts were infected with gTBwt (MOI = 1 PFU/cell) for 24 h (w/CMV) or left uninfected (w/o
CMV). Whole cell extracts were prepared, and IE1 and β-tubulin (TUBB) steady-state protein levels were analyzed by SDS-PAGE/Western blot. (C) Complex formation between IE1 and
STAT2. A549/pr(ISRE).GFP cells with inducible expression of Luc, HA-tagged IE1 or HA-tagged IE1dl410-420 were treated with doxycycline for 48 h. Whole cell extracts were prepared
and used for immunoprecipitations with anti-HA-agarose. Samples of lysates and immunoprecipitates (IPs) were analyzed by SDS-PAGE/Western blot for IE1 (HA antibody) and STAT2.
(D) Western blot analysis of the eﬀects IE1 exerts on IFN signaling and IFN induction. A549/pr(ISRE).GFP and A549/pr(IFNβ).GFP cells without (−) or with inducible expression of Luc,
HA-tagged IE1 or HA-tagged IE1dl410-420 were seeded in the presence (w/Dox) or absence (w/o Dox) of doxycycline and treated with IFNα (A549/pr(ISRE).GFP cell-lines) or UV-
inactivated, pp65-deﬁcient CMV (A549/pr(IFNβ).GFP cell-lines) for 48 h. Whole cell extracts were prepared and IE1 (HA antibody), eGFP, β-tubulin (TUBB) and MxA protein levels were
analyzed by SDS-PAGE/Western blot. (E) Immunoﬂuorescence analysis of the eﬀects IE1 exerts on IFN signaling. A549/pr(ISRE).GFP-IE1 cells were seeded in the presence (w/Dox) or
absence (w/o Dox) of doxycycline and treated with IFNα (w/IFNα) or solvent (w/o IFNα) for 24 h. Paraformaldehyde-ﬁxed samples were simultaneously reacted with a rat monoclonal
antibody to HA-tagged IE1 and a mouse monoclonal antibody to eGFP, followed by incubation with a rat-speciﬁc Alexa Fluor 594 conjugate and a mouse-speciﬁc Alexa Fluor 488
conjugate. Host cell nuclei were visualized by DAPI staining. (F) Eﬀect of IE1 expression on eGFP ﬂuorescence intensity upon activation of the IFN signaling pathway. A549/pr
(ISRE).GFP-IE1 cells were seeded in the presence or absence of doxycycline and treated with IFNα or solvent for 48 h. Fluorescence intensity was measured using an Inﬁnite-M200-Pro
microplate reader. Means and SDs of triplicate samples are shown in comparison to untreated cells (set to 1). Statistical signiﬁcance was assessed using a two-tailed, unpaired/equal
variance T-test; ****, p < 0.0001.
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Fig. 8. Single-point high-throughput screen
to identify compounds that inhibit the IFN
signaling antagonist function of CMV IE1.
The plate layout illustrating positive and nega-
tive controls (A), the timing of treatments (B),
signal-to-background (S/B) ratios of doxycy-
cline-induced IFN-treated to uninduced IFN-
treated cells (C), coeﬃcients of variation (%CV)
of uninduced (w/o Dox) and induced (w/Dox)
cells (D) and Z′ Factor values (E) for the 50,384-
well assay plates of the primary screen are
shown.
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To further assess the antiviral eﬀect of StA-IE1-2 and StA-IE1-3 a
CMV plaque reduction assay was performed (Fig. 11). The EC50 of GCV,
the current gold standard for the treatment of CMV diseases, was de-
termined to be 3.2 μM, consistent with previous reports (see for ex-
ample (Landry et al., 2000)). Notably, the StA-IE1 compounds were
even more potent than GCV in inhibiting CMV plaque formation in
MRC-5 cells with EC50 values of 2.1 μM and 1.6 μM for StA-IE1-2 and
StA-IE1-3, respectively (Fig. 11A). The situation was slightly diﬀerent
in human dermal ﬁbroblasts lacking the IE1 target STAT2. In these IFN-
signaling-deﬁcient cells the StA-IE1 compounds were outperformed by
GCV which exhibited a 1.9- and 2.8-fold lower EC50 value compared to
StA-IE1-2 and StA-IE1-3, respectively (Fig. 11B).
Taken together, our results indicate that StA-IE1-2 and StA-IE1-3
reduce viral major IE gene transcription resulting in lower IE1/IE2
protein levels and, consequently, impaired CMV replication. Since CMV
IE gene products are multifunctional proteins that perform vital roles in
virus replication beyond IFN antagonism, the two StA-IE1 compounds
are expected to have pleiotropic antiviral eﬀects in vivo. This view is
supported by the observation that StA-IE1-2 and StA-IE1-3 are eﬀective
both in STAT2-positive and STAT2-negative cells (Fig. 11A and B).
The ﬁnding that StA-IE1-2 and StA-IE1-3 inhibit CMV replication by
interfering with transcription of IE1 is unexpected given that our
platform was set up to screen for inhibitors targeting IFN antagonists at
the protein rather than the mRNA level. The inhibitors were pre-
sumably identiﬁed because IE1 expression is driven by major IE pro-
moter sequences in both the lentivirus reporter used for screening, as
well as the natural context of the CMV genome. Although structurally
unrelated, StA-IE1-2 and StA-IE1-3 both likely act as potent inhibitors
of the CMV major IE promoter, perhaps by targeting a cellular tran-
scription factor or upstream signaling protein. Interestingly, a previous
cell-based screen for inhibitors of very early events in CMV infection
identiﬁed a compound (DPPC) identical to StA-IE1-3 (Fukui et al.,
2008). DPPC was shown to disrupt CMV infection after viral entry but
before IE gene expression, consistent with our results for StA-IE1-3. To
our knowledge, StA-IE1-2 has not been previously linked to inhibition
of CMV or any other virus. StA-IE1-2 and StA-IE1-3 have the potential
to be further developed into novel drugs that may complement or re-
place existing antiviral strategies for CMV, that have traditionally tar-
geted viral DNA replication rather than IE gene expression.
4. Conclusion
We have successfully developed and executed a novel modular cell-
based platform that facilitates the safe and rapid screening for inhibitors
of potentially any viral IFN antagonist of choice. The assay's power and
ﬂexibility stems from utilizing the same validated reporter cell-lines as a
platform that can be used to rapidly generate a suite of cell-lines ex-
pressing diﬀerent target viral IFN antagonists, but which readout the
same pathway endpoint reporter gene. The optimal assay format utilizes
inducible expression of the IFN antagonist in the reporter cell-line, as
described here for CMV IE1. This is because it facilitates maximum/
minimum set points and statistical parameters Z′ factor and S/B ratio
(which require a signal window to be calculated) to be determined using
a single reporter cell-line expressing a viral IFN antagonist of choice. Our
assay negates the need to laboriously develop and validate a unique
biochemical assay for each viral IFN antagonist and permits simulta-
neous HTS, oﬀering power to control for oﬀ-target eﬀects. Additionally,
the assays simplicity and “oﬀ-the-shelf-potential” make them very ap-
plicable for rapidly responding to emerging viral infections and costly,
time-consuming high bio-containment facilities are not required as only
Fig. 9. Validation of repurchased StA-IE1 hit compounds in the A549/pr(ISRE).GFP reporter cell-lines. (A) Chemical structures of hit compounds StA-IE1-1, StA-IE1-2, and StA-IE1-
3. (B) A549/pr(ISRE).GFP reporter (parental) and A549/pr(ISRE).GFP-NS2 cells as well as (C) doxycycline-induced A549/pr(ISRE).GFP-Luc and A549/pr(ISRE).GFP-IE1 cells were
treated with DMSO or 20 μM StA-IE1-1, StA-IE1-2 or StA-IE1-3 for 2 h before the addition of 2000 U/ml IFNα. Cells were harvested 48 h later and whole cell extracts were prepared and
analyzed by SDS-PAGE/Western blot for eGFP, GAPDH, and NS2 (B) or eGFP, GAPDH, and IE1 (C).
A. Vasou et al. Antiviral Research 150 (2018) 79–92
89
Fig. 10. StA-IE1-2 and StA-IE1-3 inhibit CMV major IE gene expression and CMV replication. (A) MRC-5 ﬁbroblasts were infected with gTBwt at an MOI of 1 PFU/cell in the absence
(−) or presence of DMSO or 20 μM compound. Whole cell extracts were prepared at 8 h post-infection, and IE1, IE2, pp65 and α-tubulin (TUBA) protein levels were analyzed by SDS-
PAGE/Western blot. (B) MRC-5 ﬁbroblasts were infected with gTBwt at an MOI of 1 PFU/cell in the presence of DMSO or 20 μM compound for 8 h. Relative mRNA expression levels were
determined by RT-qPCR with primers speciﬁc for IE1 exon 4. Results were normalized to β-tubulin and mean values with SDs from two biological and two technical replicates are shown
in comparison to DMSO (set to 1). Statistical signiﬁcance was assessed using a two-tailed, unpaired/equal variance T-test; **, p < 0.01; ****, p < 0.0001. (C) MRC-5 ﬁbroblasts were
infected with gTBwt at an MOI of 0.5 PFU/cell in the presence of DMSO or 20 μM compound. eGFP expression from the viral genome was assessed at 48 h post-infection by ﬂuorescence
microscopy. (D) MRC-5 ﬁbroblasts were infected with gTBwt at an MOI of 0.5 PFU/cell in the presence of two-fold serial dilutions (40 μM-312.5 nM) of compound StA-IE1-2 (left) or StA-
IE1-3 (right). At 72 h post-infection, cells were ﬁxed with formaldehyde and eGFP expression from the viral genome was measured using an Inﬁnite-M200-Pro microplate reader. Means
and SDs of triplicate samples are shown in comparison to DMSO-treated cells (set to 1). (E) MRC-5 ﬁbroblasts were cultivated in the presence of two-fold serial dilutions (50 μM-
195.3 nM) of compound StA-IE1-2 or StA-IE1-3 for 72 h. Cells attached to the bottom of the plate were stained with crystal violet and absorbance at 570 nm was measured. Means and SDs
of triplicate samples are shown in comparison to DMSO-treated cells (set to 1). (F) MRC-5 ﬁbroblasts were infected with gTBwt at an MOI of 3 PFU/cell in the presence of DMSO or 20 μM
compound. Viral replication was assessed at day 4 post infection by qPCR-based relative quantiﬁcation of CMV DNA from culture supernatants with oligonucleotide primers speciﬁc for
the viral UL86 sequence. Data are presented as means and SDs from two biological and two technical replicates relative to DMSO-treated cells (set to 1).
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the target viral IFN antagonist is expressed without the need for re-
plication competent virus. The fact that almost all viruses encode a viral
IFN antagonist delivers the potential to screen for and develop com-
pounds to treat a wide range of important viral diseases.
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